SCHEMBL329556

SCHEMBL329556

[O]c1cccc2c1[nH]c1ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.59
ALDH1A1 P00352 4/20 0.54
HSD17B10 Q99714 3/20 0.54
GPR3 P46089 2/20 0.54
GABRP O00591 2/20 0.52
GABRD O14764 2/20 0.52
GABRA1 P14867 2/20 0.52
GABRB1 P18505 2/20 0.52
GABRG2 P18507 2/20 0.52
GABRB3 P28472 2/20 0.52
GABRA5 P31644 2/20 0.52
GABRA3 P34903 2/20 0.52
GABRA2 P47869 2/20 0.52
GABRB2 P47870 2/20 0.52
GABRA4 P48169 2/20 0.52
GABRE P78334 2/20 0.52
GABRA6 Q16445 2/20 0.52
GABRG1 Q8N1C3 2/20 0.52
GABRG3 Q99928 2/20 0.52
GABRQ Q9UN88 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347934 0.84 PARP14 (0.55) KIF11GABRPGABRDGABRA1GABRB1
SCHEMBL191347 0.79 KIF11 (0.71) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL29378455 0.79 KIF11 (0.71) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL13563976 0.79 KIF11 (0.78) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL291117 0.78 KIF11 (0.59) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL208113 0.77 KIF11 (0.63) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL29733506 0.77 KIF11 (0.63) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL29217043 0.77 KIF11 (0.57) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL16694287 0.77 KIF11 (0.57) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL10662808 0.77 KIF11 (0.57) KIF11ALDH1A1HSD17B10GPR3GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110357880-B Folded body-based chiral fluorescent compound with circular polarization luminescence property and preparation method and application thereof 北京师范大学 2020-07-03 CN claimed
EP-1426361-B1 Novel composition containing a bi-cyclic compound and a glyceride SUCAMPO AG (CH) 2008-07-30 EP claimed
WO-2024117109-A1 COMPOSITION FOR FORMING LIGHT EMITTING LAYER OF ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT AND METHOD FOR PRODUCING SAME, AND DISPLAY DEVICE 三菱ケミカル株式会社 2024-06-06 WO disclosed
EP-4366733-A1 TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF LANDOS BIOPHARMA, INC. (US) 2024-05-15 EP disclosed
CN-117835980-A Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof 朗多生物制药股份有限公司 2024-04-05 CN disclosed
EP-3927427-B1 LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME NIMMUNE BIOPHARMA INC (US) 2024-02-07 EP disclosed
US-20230422536-A1 ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2023-12-28 US disclosed
US-20230357744-A1 ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2023-11-09 US disclosed
EP-4230615-A1 ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE Hodogaya Chemical Co., Ltd. (JP) 2023-08-23 EP disclosed
EP-4225315-A2 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES Nimmune Biopharma, Inc. (US) 2023-08-16 EP disclosed
EP-4214200-A1 LANCL LIGANDS Nimmune Biopharma, Inc. (US) 2023-07-26 EP disclosed
WO-2003011814-A1 NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC NOVO NORDISK A/S (DK) 2003-02-13 WO disclosed
EP-1180765-A1 Optical recording medium and porphycene compound Mitsui Chemicals, Inc. (JP) 2002-02-20 EP disclosed
EP-1136469-A1 AMINE COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME Idemitsu Kosan Co., Ltd. (JP) 2001-09-26 EP disclosed
US-6005128-A Silacyclopentadiene derivative CHISSO CORPORATION (JP) 1999-12-21 US disclosed
EP-0864573-A2 Silacyclopentadiene derivative CHISSO CORPORATION (JP) 1998-09-16 EP disclosed
EP-0483851-B1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives MITSUBISHI CHEM CORP (JP) 1996-03-13 EP disclosed
US-5128350-A PYRAZOLYL ACRYLIC ACID DERIVATIVES AND AGRICULTURAL/HORTICULTURAL FUNGICIDES CONTAINING SAID DERIVATIVES MITSUBISHI KASEI CORPORATION (JP) 1992-07-07 US disclosed
EP-0483851-A1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives Mitsubishi Chemical Corporation (JP) 1992-05-06 EP disclosed
US-3941710-A Phosphate - free dishwashing compositions containing an alkyl polyether carboxylate surfactant LEVER BROTHERS COMPANY (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230422536-A1 ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE AHR, ARNT, SLC7A5 KIF11 2690/4885ALDH1A1 739/4885HSD17B10 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.